Sunday, Nov. 22, 2026 A Vik Media Group publication
Mongevity Longevity in Motion
Leer en español

Early TB drugs did not help more infants with HIV and severe lung infections survive

Infections and vaccines after 50Part of a story we are following · 10 articles · See every update
A straw sun hat and sunglasses resting on rocks by the sea on a sunny day.
A straw sun hat and sunglasses resting on rocks by the sea on a sunny day.Photo: Jernej Furman from Slovenia / Wikimedia Commons, CC BY 2.0

This is a hard story, and it is fine to feel sad reading it. Many babies with HIV who get severe pneumonia still die, and doctors are looking for anything that could change that. One idea was to treat every one of these babies for tuberculosis right away, in case TB was hiding behind the lung infection. A large trial has now tested that idea, and it did not show a survival gain.

In a trial of 558 infants with HIV and severe pneumonia, aged 28 days to 365 days, in six African countries, giving tuberculosis treatment to every infant from the start did not lead to better survival than treating TB only when tests or doctors’ judgment pointed to it. These severe lung infections remain very dangerous, and this trial did not find a new way to lower that danger.

How the study worked

The EMPIRICAL trial was a randomized controlled trial, the kind of study that compares groups chosen by chance. It took place in 19 hospitals in Côte d’Ivoire, Malawi, Mozambique, Uganda, Zambia and Zimbabwe. Between March 15, 2020 and January 31, 2024, 563 infants were enrolled, and 558 were included in the results after five were found not to meet the entry rules. Their median age was about 4 months.

All infants got standard care for bacterial pneumonia and for a lung infection called Pneumocystis pneumonia. One group also got six months of four-drug TB treatment right away. The other group was treated for TB only if a test came back positive or if a doctor suspected TB during follow-up. The results were published on November 14, 2026 in Lancet. One limit: many infants in the comparison group ended up getting TB treatment anyway, which may have made the two approaches look more alike than they really are.

What they found

Survival was not better with TB treatment for everyone. At 12 months, 132 of 276 infants (48%) in the groups that got TB treatment up front had died. In the groups that did not, 121 of 282 infants (43%) had died. Statistically, that gap is not a real difference, so the trial cannot say that one approach was better than the other. The same was true at 15 days: no clear difference between the groups.

The “wait and test” approach was not really a “never treat” approach. In that group, 130 of 282 infants (46%) did start TB treatment, usually about 4 days after joining the study. For 55 infants (20%), a positive test led to treatment. For 75 infants (27%), the treating doctor decided on clinical grounds, including what the chest images showed. In other words, doctors using the guided approach found and treated TB in nearly half of these babies.

Safety looked similar in both groups. Serious side effects did not differ, and there were no deaths linked to the treatment. The most common problems were also about the same in both groups:

Problem TB treatment for all Guided approach
Anemia (low red blood cells) 163 of 276 (59%) 169 of 282 (60%)
Raised liver enzymes 72 of 276 (26%) 74 of 282 (26%)
Another infection needing medicine 161 of 276 (58%) 176 of 282 (62%)

What else did the trial test?

The trial had a second part. Some infants also got 15 days of valganciclovir, an antiviral medicine. The study looked at whether the antiviral and the TB treatment affected each other, and it found no sign that they did. This article covers only the TB comparison.

What you can do today

There is no new step for you from this result, and current advice does not change. The approach doctors already recommend, which is to test for TB and treat it when results or clinical signs point to it, held up well in this trial. If you follow global health news, you can keep in mind that treating every infant for TB “just in case” did not save more lives here.

For clinicians and researchers

Design: Multicentre, open-label, 2×2 factorial randomised superiority trial in 19 hospitals across six African countries; infants aged 28-365 days with severe HIV-associated pneumonia; 558 analysed. Empirical tuberculosis treatment (eTB-T) was compared with a clinically and microbiologically guided strategy.

Main result: All-cause mortality at 12 months was 132 (48%) of 276 with eTB-T versus 121 (43%) of 282 without; the difference in the risk of death was not statistically clear (p=0·3868). At 15 days, the difference in deaths was also not statistically clear (p=0·2950). No superiority was shown.

Main limitation: Open-label design; 130 (46%) of 282 infants in the non-eTB-T groups eventually started tuberculosis treatment, which may have reduced the contrast between strategies and attenuated detection of differences.

Open question: Whether a strategy contrast less diluted by later treatment initiation, or other approaches to reduce mortality in infants with HIV-associated pneumonia, would show a survival difference remains untested.

Trial registry: NCT03915366

Also cited: Lancet · NCT03915366

Got a question? Ask us ›

Get the best of longevity science by emailThe most useful new studies, in plain language and with the source. Free.

We'll email you once to confirm. Occasional messages from our sponsors, clearly labeled. Unsubscribe anytime. We never ask for health data.
Cite this article
AMA
Mongevity Desk. Early TB drugs did not help more infants with HIV and severe lung infections survive. Mongevity. Published November 18, 2026. Accessed November 22, 2026. https://mongevity.science/immunity/2026/11/early-tb-treatment-infants-hiv-pneumonia-trial/
Vancouver
Mongevity Desk. Early TB drugs did not help more infants with HIV and severe lung infections survive [Internet]. Mongevity; 2026 Nov 18 cited 2026 Nov 22]. Available from: https://mongevity.science/immunity/2026/11/early-tb-treatment-infants-hiv-pneumonia-trial/
APA
Mongevity Desk. (2026, November 18). Early TB drugs did not help more infants with HIV and severe lung infections survive. Mongevity. https://mongevity.science/immunity/2026/11/early-tb-treatment-infants-hiv-pneumonia-trial/
For your website
<a href="https://mongevity.science/immunity/2026/11/early-tb-treatment-infants-hiv-pneumonia-trial/">Early TB drugs did not help more infants with HIV and severe lung infections survive</a>

Free to share or quote with credit and a link.

Questions and answers

Did treating every infant for TB help them survive?
No clear gain was found. At 12 months, 48% of infants given TB treatment up front had died, compared with 43% of those treated only when tests or doctors suggested TB.
Was the TB treatment unsafe?
No. Serious side effects were similar in both groups, and there were no deaths linked to the treatment.
Does this mean TB treatment is not needed for these infants?
No. In the guided group, 130 of 282 infants (46%) still received TB treatment when tests or doctors pointed to it.
Who was studied?
The trial included 558 infants aged 28 to 365 days with HIV and severe pneumonia, treated at 19 hospitals in six African countries.

Sources

  1. Lancet: Empirical tuberculosis treatment in infants living with HIV hospitalised with severe pneumonia in Africa (EMPIRICAL): a multicentre, randomised, open-label, 2 × 2 factorial, controlled superiority trial (PMID 43020097 · DOI 10.1016/s0140-6736(26)01418-2) · 2026-11-18

More on this story

Report an error